| Cat. No. |
Product Name |
Information |
| PC-21636 |
Ningetinib
MET/AXL inhibitor
|
Ningetinib (CT053PTSA) is a potent, orally bioavailable multikinase inhibitor against c-Met, VEGFR2 as well as Axl, Mer, and FLT3, shows IC50s of 6.7, 1.9 and < 1.0 nM against c-Met, VEGFR-2 and Axl in cell-based assays. |
| PC-20461 |
Tepotinib
MET inhibitor
|
Tepotinib (EMD1214063, MSC2156119) is a potent, specific and ATP-competitive inhibitor of MET (HGFR) with IC50 of 23 nM for MET WT autophosphorylation and 2.2-42.6 nM for M1268T, Y1248H, H1112Y, L1213V, H1112L, V1110I, V1206L, and V1238I MET-mutated variants. |
| PC-20333 |
Merestinib
c-Met inhibitor
|
Merestinib (LY2801653) is a potent, selective, type-II ATP competitive inhibitor of c-Met with Ki of 2 nM, inhibits c-MET wt and mutant Y1230C with IC50 of 42 and 54 nM, respectively. |
| PC-20053 |
BAY-474
c-Met inhibitor
|
BAY-474 (BAY474) is a potent selective inhibitor of c-MET (Tyrosine-protein Kinase Met) with IC50 of <1 nM. |
| PC-49518 |
SYN1143
c-Met/Ron inhibitor
|
SYN1143 (AMG-1) is a potent specific small molecule inhibitor of c-Met kinase and RON with IC50 of 4 and 9 nM, inhibits c-Met signaling and cell proliferation in vitro. |
| PC-49517 |
OSI-296
c-Met/Ron inhibitor
|
OSI-296 is a potent and selective inhibitor of c-MET and RON kinases with cellular IC50 of 42 and 200 nM, respectively. |
| PC-49516 |
LCRF-0004
Ron kinase inhibitor
|
LCRF-0004 is a potent and selective RON receptor tyrosine kinase inhibitor with IC50 of 50 nM (ELISA), weakly inhibits c-Met with IC50 of 150 nM and does not inhibit VEGFR2. |
| PC-49513 |
XL092
VEGFR/MET/TAM inhibitor
|
XL092 (XL-092) is a novel small molecule multi-receptor tyrosine kinase (RTK) inhibitor, targets MET (IC50=3.0 nM), VEGFR2 (IC50=15.0 nM), and the TAM kinases TYRO3, AXL (IC50=5.8 nM), and MER (IC50=0.6 nM). |
| PC-49451 |
D6808
c-MET inhibitor
|
D6808 is a highly selective and potent macrocyclic c-Met inhibitor with IC50 of 2.9 nM. |
| PC-49280 |
c-MET inhibitor 7
c-MET inhibitor
|
c-MET inhibitor 7 is a potent, highly selective c-MET inhibitor with IC50 of 0.90 and 0.09 μM for wild-type and D1228V c-MET, respectively. |
| PC-49132 |
Dalmelitinib
c-Met inhibitor
|
Dalmelitinib is a potent, selective c-Met tyrosine kinase inhibitor with IC50 of 0.7 nM, inhibits cell growth of gastric cells SNU5 with IC50 of 2.0 nM, binds to the ATP-binding region of c-MET kinase. |
| PC-38624 |
Altiratinib
MET/TIE-2/VEGFR inhibitor
|
Altiratinib (DCC-2701) is a potent c-MET/TIE-2/VEGFR inhibitor with IC50 of 2.7 nM (MET WT), 8.0 nM (TIE2 kinase) and 9.2 nM (VEGFR2), also potently inhibits oncogenic MET mutations in the switch region (residues 1228, 1230, and 1250) with IC50 range of 0.37-6 nM. |
